- Tetra Bio-Pharma Inc. (TBP) has submitted a US$750,000 grant application to the Biomedical Advanced Research and Development Authority
- The application is in regard to the use of its collaboration partner’s Prepaire Shield platform to assess repurposed drugs combined with onternabez
- This was designed to improve the management of patients exposed to pulmonary or nerve chemical agents to minimize the outcome following mass casualty events
- Onternabez is a selective activator of the cannabinoid type two receptor, which is an important target for the healthy regulation of the central nervous and immune systems
- Tetra Bio-Pharma Inc. (TBP) is unchanged, trading at $0.04 per share as of 3:38 p.m. ET
Tetra Bio-Pharma (TBP) has submitted a US$750,000 grant application to the Biomedical Advanced Research and Development Authority.
The grant is in regard to the use of its collaboration partner’s Prepaire Shield platform to assess repurposed drugs combined with onternabez.
The collaboration project is designed to improve the management of patients exposed to pulmonary or nerve chemical agents to minimize the outcome following mass casualty events.
Prepaire Shield is a multi-level data solution that uses artificial intelligence (AI) to generate potential combination treatments with in vitro testing using induced pluripotent stem cells and a tool to help develop a clinical decision support system.
Any newly identified therapies will include repurposed drugs combined with Tetra’s investigational compound, onternabez, to treat acute and long-term effects of pulmonary and nerve chemical war agents (CWAs).
Onternabez is a selective activator of the cannabinoid type two receptor, which is an important target for the healthy regulation of the central nervous and immune systems.
Tetra believes that ornternabez has the potential to help patients who have been exposed to a pulmonary CWA through a combination of treatments that address the acute symptoms.
Additionally, patients exposed to nerve chemical agents could benefit from the new drug synthesis models, which may be administered together with an anti-inflammatory and neuroprotectant agent to prevent long-term neuro-deficiency.
Tetra Bio-Pharma Inc. (TBP) is unchanged, trading at $0.04 per share as of 3:38 p.m. ET.
